Recently, Mitsdoerffer et al. [70] found that the transcriptome of CD8+ TILs in GBM was coherent with a strong anti-tumor response, while that one of CD4+ TILs showed a strong commitment to the Th17 differentiation that may negatively modulate the anti-tumor immune response. The gene discussed is CD8A; the disease is neoplasm.